MX2022012610A - Metodos para tratar anemia usando una trampa de ligando de receptor de activina de tipo iib (actriib) y fedratinib. - Google Patents

Metodos para tratar anemia usando una trampa de ligando de receptor de activina de tipo iib (actriib) y fedratinib.

Info

Publication number
MX2022012610A
MX2022012610A MX2022012610A MX2022012610A MX2022012610A MX 2022012610 A MX2022012610 A MX 2022012610A MX 2022012610 A MX2022012610 A MX 2022012610A MX 2022012610 A MX2022012610 A MX 2022012610A MX 2022012610 A MX2022012610 A MX 2022012610A
Authority
MX
Mexico
Prior art keywords
fedratinib
methods
treating anemia
ligand trap
subject
Prior art date
Application number
MX2022012610A
Other languages
English (en)
Inventor
Abderrahmane Laadem
Steve Ritland
Jay T Backstrom
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2022012610A publication Critical patent/MX2022012610A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento se proporcionan métodos para tratar la anemia en un sujeto que lo necesite, que comprenden administrar al sujeto una trampa de ligando de receptor de activina de tipo IIB (ActRIIB) y administrar al sujeto fedratinib. Específicamente, el método comprende realizar una medición del nivel de hemoglobina (Hgb) en el sujeto antes y después de la administración.
MX2022012610A 2020-04-13 2021-04-12 Metodos para tratar anemia usando una trampa de ligando de receptor de activina de tipo iib (actriib) y fedratinib. MX2022012610A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063009400P 2020-04-13 2020-04-13
PCT/US2021/026816 WO2021211418A1 (en) 2020-04-13 2021-04-12 Methods for treating anemia using an actriib ligand trap and fedratinib

Publications (1)

Publication Number Publication Date
MX2022012610A true MX2022012610A (es) 2022-11-07

Family

ID=78085002

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012610A MX2022012610A (es) 2020-04-13 2021-04-12 Metodos para tratar anemia usando una trampa de ligando de receptor de activina de tipo iib (actriib) y fedratinib.

Country Status (10)

Country Link
US (1) US20230181690A1 (es)
EP (1) EP4135736A1 (es)
JP (1) JP2023523568A (es)
KR (1) KR20230003502A (es)
CN (1) CN115427056A (es)
AU (1) AU2021256419A1 (es)
BR (1) BR112022020628A2 (es)
IL (1) IL297258A (es)
MX (1) MX2022012610A (es)
WO (1) WO2021211418A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3294320A4 (en) * 2015-05-13 2018-12-26 Celgene Corporation Treatment of beta-thalassemia using actrii ligand traps
EP3490582A4 (en) * 2016-07-27 2020-04-01 Acceleron Pharma Inc. METHOD AND COMPOSITIONS FOR TREATING MYELOFIBROSE
WO2018053142A2 (en) * 2016-09-14 2018-03-22 President And Fellows Of Harvard College Methods and compositions for modulating erythropoiesis

Also Published As

Publication number Publication date
IL297258A (en) 2022-12-01
BR112022020628A2 (pt) 2022-11-29
CN115427056A (zh) 2022-12-02
KR20230003502A (ko) 2023-01-06
EP4135736A1 (en) 2023-02-22
WO2021211418A1 (en) 2021-10-21
US20230181690A1 (en) 2023-06-15
AU2021256419A1 (en) 2022-10-20
JP2023523568A (ja) 2023-06-06

Similar Documents

Publication Publication Date Title
Kordbacheh et al. Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms
Cavaletti Chemotherapy‐induced peripheral neurotoxicity (CIPN): what we need and what we know
Xie et al. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer
Webb et al. Randomized, double-blind, controlled study of losartan in children with proteinuria
Cohen‐Wolkowiez et al. Safety and pharmacokinetics of multiple‐dose anidulafungin in infants and neonates
MX2023010900A (es) Anticuerpo anti-cd20 de tipo ii y usos del mismo.
EA201590210A1 (ru) Контроль над токсичностью в случае противоопухолевой активности химерных антигенных рецепторов
FI3227675T3 (fi) Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi
MX2022012610A (es) Metodos para tratar anemia usando una trampa de ligando de receptor de activina de tipo iib (actriib) y fedratinib.
Spigel et al. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study
NZ601111A (en) Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
MX2019005141A (es) Efecto protector de dmpc, dmpg, dmpc/dmpg, lisopg y lisopc contra fármacos que causan canalopatías.
Nguyen et al. Pazopanib: approval for soft-tissue sarcoma
MX2019006131A (es) Metodos para tratar cancer de mama positivo para prlr.
Hong et al. A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma
ZA202204075B (en) Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof
Cox et al. The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma
Lu et al. Model‐based meta‐analysis for quantifying Paclitaxel dose response in cancer patients
MX2022006786A (es) Método de tratamiento de cáncer mediante la administración de un agente terapéutico anti-pd-1 o anti-pd-l1 mediante un dispositivo de administración linfática.
Shukuya et al. Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients
MX2022006891A (es) Terapia combinada con liv1-adc y antagonista de pd-1.
MX2022014080A (es) Metodos y composiciones para tratar la anemia usando trampas de ligando de activina de tipo iib (actriib) e inhibidores de la diana de rapamicina en celulas de mamifero (mtor).
EP4233842A3 (en) Avexitide for the treatment of hyperinsulinemic hypoglycemia
Esteban et al. Sofosbuvir/velpatasvir is effective and safe in patients with concomitant proton pump inhibitor use in clinical studies
Azadeh et al. Cetuximab plus various chemotherapy regimens for patients with KRAS wild-type metastatic colorectal cancer